Assenagon Asset Management S.A. Buys 419,656 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Assenagon Asset Management S.A. increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 314.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 553,114 shares of the company's stock after buying an additional 419,656 shares during the period. Assenagon Asset Management S.A. owned 1.20% of Pacira BioSciences worth $8,324,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Pacira BioSciences by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock valued at $149,413,000 after purchasing an additional 14,960 shares during the period. Pacer Advisors Inc. lifted its position in Pacira BioSciences by 37.5% during the second quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company's stock valued at $61,877,000 after buying an additional 590,082 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Pacira BioSciences by 9.8% during the 2nd quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company's stock valued at $59,114,000 after buying an additional 184,000 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Pacira BioSciences by 12.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company's stock worth $52,300,000 after buying an additional 198,936 shares during the period. Finally, Clearbridge Investments LLC increased its stake in shares of Pacira BioSciences by 2.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company's stock worth $34,250,000 after acquiring an additional 26,463 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

Insider Buying and Selling at Pacira BioSciences

In other news, CEO Frank D. Lee bought 8,264 shares of the company's stock in a transaction on Monday, August 12th. The shares were acquired at an average cost of $12.10 per share, with a total value of $99,994.40. Following the completion of the transaction, the chief executive officer now owns 107,784 shares of the company's stock, valued at approximately $1,304,186.40. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders purchased 11,176 shares of company stock worth $136,240. Insiders own 6.40% of the company's stock.

Pacira BioSciences Stock Performance

NASDAQ PCRX traded up $0.05 during trading hours on Tuesday, hitting $17.18. The company's stock had a trading volume of 409,194 shares, compared to its average volume of 873,594. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The company's 50 day simple moving average is $15.16 and its two-hundred day simple moving average is $21.52. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.82 and a quick ratio of 5.70. The company has a market cap of $799.66 million, a P/E ratio of 11.98 and a beta of 0.84.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.53 by $0.11. The firm had revenue of $178.02 million during the quarter, compared to analyst estimates of $173.31 million. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. As a group, sell-side analysts expect that Pacira BioSciences, Inc. will post 2.2 EPS for the current fiscal year.

Analyst Ratings Changes

PCRX has been the topic of a number of recent research reports. Needham & Company LLC cut their price objective on shares of Pacira BioSciences from $43.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, August 12th. HC Wainwright reduced their price objective on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating for the company in a research report on Monday, August 12th. StockNews.com cut Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 12th. Piper Sandler cut Pacira BioSciences from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $42.00 to $11.00 in a research note on Monday, August 12th. Finally, Barclays lowered Pacira BioSciences from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $38.00 to $25.00 in a research report on Wednesday, July 3rd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $24.20.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.